Manufacturer end adefovir development.
Gilead Sciences has stopped development of its drug, adefovir, for use against HIV infection. This news came after the Food and Drug Administration (FDA) informed Gilead that adefovir would not be approved based on existing data and that additional studies would be necessary if it wants the FDA to reconsider the matter. The Antiviral Drugs Advisory Committee to the FDA had earlier recommended that the drug not be approved on the grounds that its potential serious side effects outweighed its potential benefits.
D000225:Adenine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; C053001:adefovir; D000225:Adenine